You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an integrated 4-organ animal model

    SBC: HESPEROS, INC            Topic: NIEHS

    Project Summary/AbstractWe propose to construct multi organ microphysiological systems (“Body-on-a-Chip” or BoaCs) from human and rat cells to use as a basis to understand species differences in response to exposure to drugs or chemicals in this new platform. The results will then be compared to clinical data, where available, and to archived in vivo animal data. This work will directly test w ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.

    SBC: RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC            Topic: 101

    Project SummaryRadiopharmaceutical therapy (RPT) – the use of targeted radionuclides to deliver radiation specifically to cancer cells and their microenvironment – is a fundamentally different approach to cancer therapy that is growing, with a substantial number of large and small pharmaceuticals companies developing products in this area and radionuclide producers making substantial investmen ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Automation and Performance-Based Selection to Improve the Reproducibility of MSCs

    SBC: Cell X Technologies, Inc.            Topic: 400

    Project Summary The purpose of this proposal is to advance the field of Mesenchymal Stromal CellMSCbiology and particularly the process of translating MSCs into safe and effective therapiesThe Broad Aim of this proposal is to demonstrate that the Cell Xautomation platform enables users to generate culture expanded humanmesenchymal stem stromal cellpopulationshMSCswith greater quality and with less ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. An integrated electrical impedance myography platform for neuromuscular disease classification and diagnosis

    SBC: MYOLEX, INC.            Topic: 103

    Project SummaryImproved methods for the bedside diagnosis and evaluation of neuromuscular disorders are needed. One technology that is finding increasing use for this purpose is electrical impedance myography (EIM). In EIM, a very weak, high frequency electrical current is passed through a muscle of interest and the resulting surface voltages are measured. Disease associated alterations in the com ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. An Advanced Lung Organomimetic to Reproduce Human Airway Pathophysiology

    SBC: PNEUMAX, LLC            Topic: 113

    PROJECT SUMMARYThree of top five causes of death in humans globally are lung relatedchronic obstructive pulmonary diseaseCOPDlower respiratory infections and lung cancers collectively account for over eight million deaths annuallyCurrentlyin preclinical settingstatic cell cultures and animal models are the most widely used systems for mechanistic and translational studiesHowevercritical limitation ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting GSK3 in AML

    SBC: CuronBiotech Inc            Topic: 102

    Acute myeloid leukemiaAMLis one of the most common forms of leukemia in adults and despite advances in treatment theyear survival is less thanin adults and significantly lower in the elderlyThe remarkable success in treating one relatively uncommon subset of AMLacute promyelocytic leukemiawith all trans retinoic acidATRAillustrates the great promise for agents with greater efficacy and less toxici ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients

    SBC: Oncoimmune Inc            Topic: 102

    Summary Although most COVID-19 patients exhibit mild to moderate clinical symptoms, a substantial portion require hospitalization with oxygen support. These patients are classified as having severe COVID-19 and have high risk of progression to an intensive care unit (ICU) with requirement for invasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and carry high risk for morta ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government